Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Historical quarterly data presented for periods ending March 31, June 30, September 30, and December 31 from 2008 through 2010.
Issuance Date: September 10, 2010
This filing provides a revised presentation of pharmaceutical turnover by product and therapeutic area to align with the reporting structure adopted for the period ended June 30, 2010. The revision separates the Emerging Markets segment from the Rest of World, creates a new Dermatological therapeutic area, and reflects the creation of ViiV Healthcare in 2009.
Key Financial Metrics
The filing focuses exclusively on Pharmaceutical Turnover (Revenue) by product and region. It does not provide consolidated profit, cash flow, debt, or liquidity figures.
| Period Ended | Total Pharmaceutical Turnover (£m) | Constant Exchange Rate (CER) Growth | ViiV Healthcare Turnover (£m) |
|---|---|---|---|
| March 31, 2010 | 6,126 | 14% | 373 |
| December 31, 2009 | 6,910 | 15% | 412 |
| September 30, 2009 | 5,588 | 2% | 395 |
| June 30, 2009 | 5,578 | -4% | 379 |
| March 31, 2009 | 5,618 | -6% | 419 |
Note: The filing does not provide clear values for net profit, operating margins, cash flow, or total debt.
Material Changes and Trends
- Reporting Presentation: Historical data from Q1 2008 through Q2 2010 has been restated to separate Emerging Markets revenue from the Rest of World and to reclassify products into a new Dermatological category.
- Revenue Growth: Pharmaceutical turnover showed strong growth in Q4 2009 (15% CER) and Q1 2010 (14% CER), contrasting with declines in the first half of 2009.
- Product Performance (Q1 2010):
- Respiratory: Total turnover of £1,766m (6% CER growth). Seretide/Advair remained the largest contributor (£1,264m).
- Vaccines: Total turnover of £1,411m (>100% CER growth), driven significantly by Flu Pandemic vaccines (£698m).
- Anti-virals: Total turnover of £358m (-44% CER), heavily impacted by a decline in Relenza sales.
- Metabolic: Total turnover of £230m (-18% CER), with Avandia products declining 10%.
- Regional Performance (Q1 2010): Emerging Markets showed the strongest growth at 43% CER, followed by Rest of World at 35% CER. USA turnover declined 1% CER.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a cautionary statement that forward-looking projections are subject to risks and uncertainties that may cause actual results to differ materially.
- Risk Factors: Specific risks are referenced as being detailed in the "Risk Factors" section of the company's Annual Report on Form 20-F for 2009.
- Unusual Items: The significant variance in Vaccine turnover is attributed to the "Flu Pandemic" product line, which saw turnover of £698m in Q1 2010 compared to £11m in Q3 2009.
- Guidance: This specific filing does not contain new financial guidance or management commentary on future outlook beyond the historical data restatement.
Investor Verification Checklist
- Restatement Impact: Verify how the separation of Emerging Markets and the new Dermatological category affects year-over-year growth comparisons for specific products.
- Vaccine Volatility: Assess the sustainability of Vaccine revenue given the heavy reliance on "Flu Pandemic" sales in Q1 2010 versus prior periods.
- Avandia Exposure: Monitor the continued decline in Avandia product sales (-10% in Q1 2010) and potential litigation or regulatory risks associated with the Metabolic segment.
- Full Financials: Consult the full Annual Report (Form 20-F) for consolidated profit, cash flow, and debt metrics, as this filing only covers pharmaceutical turnover.
- ViiV Healthcare: Review the standalone performance of the ViiV Healthcare joint venture, which reported £373m in turnover for Q1 2010.